Novel discoveries in understanding the complexities of epilepsy and major depression

Bibliography

• Damea C, Juulb SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001;79:228-35
   PubMedGoogle Scholar
• Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-58
   PubMed Web of Science ®Google Scholar
• Brines ML, Ghezzi P, Keenan S, Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Pankratova S, Sonn K, Soroka V, Neuroprotective properties of a novel, non-hematopoietic agonist of the erythropoietin (EPO) receptor. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 538.6/O26
   Google Scholar
• Jenkinson ML, Bliss MR, Brain AT, Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-8
   PubMedGoogle Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-32
   PubMed Web of Science ®Google Scholar
• Schio F, Navarro Mora G, Pellitteri M, LPS-induced inflammation triggers epileptogenic mechanisms in pilocarpine non responsive treated rats. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 538.2/O22
   Google Scholar
• Zattoni M, Mura M, Fritschy JM, Absence of T-cells aggravates epileptogenesis and neurodegeneration in a mouse model of temporal lobe epilepsy. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 538.3/O23
   Google Scholar
• Pellitteri M, Schio F, Lodico R, New evidences of a possible role of vascular alterations and cytokines in absence epilepsy. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 538.4/O24
   Google Scholar
• Rodgers KM, Hutchinson MR, Northcutt A, The cortical innate immune response increases local neuronal excitability leading to seizures. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 538.5/O25
   Google Scholar
• Dhir A, Naidu PS, Kulkarni SK. Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: possible mechanism of action. Prog Neuropsychopharmacol Biol Psychiatr 2006;30:1478-85
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Patil CS, Kumar A, Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology 2007;79:34-41
   PubMed Web of Science ®Google Scholar
• Mazarati AM, Shin D, Sankar R, Antidepressant effects of interleukin-1 receptor antagonist in an animal model of comorbidity between temporal lobe epilepsy and depression. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 439.6/N20
   Google Scholar
• Lowson S, Gent JP, Goodchild CS. Anticonvulsant properties of propofol and thiopentone: comparison using two tests in laboratory mice. Br J Anaesth 1990;64:159-63
   PubMed Web of Science ®Google Scholar
• Bansinath M, Shukla VK, Turndorf H. Propofol modulates the effects of chemoconvulsants acting at gabaergic, glycinergic, and glutamate receptor subtypes. Anesthesiology 1995;83:809-15
   PubMed Web of Science ®Google Scholar
• Hasan Z, Khatib S, Abu-Laban A. Effects of propofol and thiopentone on picrotoxin convulsive threshold in the rabbit. Can J Physiol Pharmacol 1995;73:714-17
   PubMed Web of Science ®Google Scholar
• Dhir A, Zolkowska D, Del Cid B, Intrapulmonary propofol hemisuccinate rapidly protects against pentylenetetrazol-induced seizures in rats. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 638.20/Q1
   Google Scholar
• Heafield MTE. Managing status epilepticus: new drug offers real advantages. BMJ 2000;320:953-4
   PubMed Web of Science ®Google Scholar
• Aronica EM, Gorter JA, Paupard M, Status epilepticus-induced alterations in metabotropic glutamate receptor expression in young and adult rats. J Neurosci 1997;17:8588-95
   PubMed Web of Science ®Google Scholar
• Romero D, Mendoza MS, Romero JI, Giordano M. Memantine as adjuvant drug therapy in an animal model of epilepsy. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 242.2/I32
   Google Scholar
• Yee AS, Gonzales M, Raol Y, Wnt signaling activation following status epilepticus. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 242.2/I31
   Google Scholar
• Bassuk AG, Wallace RH, Buhr A, A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. Am J Hum Genet 2008;83:572-81
   PubMed Web of Science ®Google Scholar
• Vijayakumar L. Suicide and mental disorders in Asia. Int Rev Psychiatry 2005;17:109-14
   PubMed Web of Science ®Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Neurosci 2006;7:137-51
   Web of Science ®Google Scholar
• Blass K. Treating depression with cannabinoids. Cannabinoids 2008;3:8-10
   Google Scholar
• Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005;15:593-99
   PubMed Web of Science ®Google Scholar
• Witkin JM, Tzavara ET, Davis RJ, A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 2005;26:609-17
   PubMed Web of Science ®Google Scholar
• Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005;16:315-31
   PubMed Web of Science ®Google Scholar
• Hill MN, Hillard CJ, Bambico FR, The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009;30:484-93
   PubMed Web of Science ®Google Scholar
• McLaughlin RJ, Hill MN, Morrish AC, Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007;18:431-38
   PubMed Web of Science ®Google Scholar
• Hill MN, Ho WS, Sinopoli KJ, Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology 2006;31:2591-99
   PubMed Web of Science ®Google Scholar
• Hill MN, Carrier EJ, McLaughlin RJ, Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008;106:2322-36
   PubMed Web of Science ®Google Scholar
• Martin M, Ledent C, Parmentier M, Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002;159:379-87
   PubMed Web of Science ®Google Scholar
• Beyer CE, Piesla MJ, Dwyer JM, Depression like phenotype following chronic treatment with rimonabant: a link between CB1 receptors and mood disorders. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 60.7/N21
   Google Scholar
• Bortolato M, Mangieri RA, Fu J, Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007;62:1103-10
   PubMed Web of Science ®Google Scholar
• Piomelli D, Tarzia G, Duranti A, Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006;12:21-38
   PubMedGoogle Scholar
• Diaz A, Rodriguez-Gaztelumendi A, Rojo ML, Autoradiographic study of the functionality of brain cannabinoid CB1-receptors in the olfactory bulbectomized rat and the modulation by chronic fluoxetine. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 60.8/N22
   Google Scholar
• Rubino T, Vigano D, Realini N, Chronic Δ9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008;33:2760-71
   PubMed Web of Science ®Google Scholar
• Rubino T, Realini N, Vigano D, Involvement of the cannabinoid system in the neurobiology of depression and its therapeutical implications. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 60.6/N20
   Google Scholar
• Shearman LP, Rosko KM, Fleischer R, Antidepressant-like and anoretic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003;14:573-82
   PubMed Web of Science ®Google Scholar
• Lew R, Schreiber R, Bowen C, Pharmacological characteristics of SEP230864: application towards the treatment of neuropsychiatric diseases. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 549.7/X1
   Google Scholar
• Schreiber R, Lew R, Hardy L, Pharmacological characterization of the triple monoamine transporter uptake inhibitor SEP 225289. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 549.8/X2
   Google Scholar
• Campbell UC, Engel S, Hardy L, The novel triple reuptake inhibitor SEP-0228425 exhibits antidepressant, anxiolytic and analgesic efficacy in rodent behavioral tests. 39th Society for Neuroscience Annual Meeting (October 17-21, Chicago) 2009: 549.9/X3
   Google Scholar